Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203679 | 0.91 | PARP1 (0.83) | PARP1 | |
| SCHEMBL12750571 | 0.90 | PARP1 (1.00) | PARP1 | |
| SCHEMBL7160563 | 0.90 | PARP1 (0.80) | PARP1 | |
| SCHEMBL12750579 | 0.89 | PARP1 (0.80) | PARP1 | |
| SCHEMBL6200038 | 0.89 | PARP1 (0.80) | PARP1 | |
| SCHEMBL7158077 | 0.89 | PARP1 (1.00) | PARP1 | |
| SCHEMBL6199272 | 0.89 | PARP1 (0.80) | PARP1 | |
| SCHEMBL20570669 | 0.89 | PARP1 (0.80) | PARP1 | |
| SCHEMBL7554564 | 0.89 | PARP1 (0.80) | PARP1 | |
| SCHEMBL6202114 | 0.88 | PARP1 (0.78) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101937-A1 | ACYLHYDRAZONES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| EP-1684736-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | Kudos Pharmaceuticals Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885 |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | MET, ERBB2, ERBB3 | PARP1 2253/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PARP1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.